QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

IBRX

QT58ImmunityBio, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
7.36
+0.37+5.29%
OverviewShort InterestFilings
IBRXQT58ImmunityBio, Inc.·NASDAQ
OverviewShort InterestFilings
7.36+5.29%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.85
Insider Own26.01%
Shs Outstand1.05B
Perf Week2.22%
Market Cap7.32BForward P/E-EPS next Y-0.16Insider Trans0.17%Shs Float-Perf Month-5.15%
Enterprise Value8.24BPEG0.06EPS next Q-0.09Inst Own-Short Float-Perf Quarter-16.55%
Income-871928300.00P/S51.93EPS this Y0.00%Inst Trans-Short Ratio-Perf Half Y240.74%
Sales140.98MP/B-EPS next Y81.57%ROA-132.15%Short Interest-Perf YTD271.72%
Book/sh-0.83P/C-EPS next 5Y-ROE138.69%52W High12.43 -40.79%Perf Year159.15%
Cash/sh0.36P/FCF-EPS past 3/5Y-ROIC-44.51%52W Low1.95 277.44%Perf 3Y-
Dividend Est.-EV/EBITDA-11.35Sales past 3/5Y- 157.40%Gross Margin93.79%Volatility3.84% 4.62%Perf 5Y-
Dividend TTM-EV/Sales58.45EPS Y/Y TTM48.39%Oper. Margin-185.41%ATR (14)0.49Perf 10Y-
Dividend Ex-Date-Quick Ratio6.66Sales Y/Y TTM833.33%Profit Margin-606.15%RSI (14)50.24Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.67EPS Q/Q40.00%SMA200.98%Beta1.84Target Price13.00
Payout0.00%Debt/Eq-1.29Sales Q/Q158.82%SMA50-2.53%Rel Volume1.05Prev Close6.99
Employees671LT Debt/Eq-1.74EarningsAug 04SMA20043.32%Avg Volume13.57MPrice7.36
IPO DateJul 28, 2015Option/ShortYes / YesEPS/Sales Surpr.-12.50% 2.33%Net Debt/EBITDA-1.27Volume14,266,758Change5.29%
Analyst Ratings
DateActionAnalystRatingTarget
May-08-26ReiteratedBTIGBuy$13 → $12
Mar-04-26ReiteratedPiper SandlerOverweight$7.00 → $12
Feb-23-26ReiteratedH.C. Wainwright$10 → $15
Jan-20-26ReiteratedPiper SandlerOverweight$7.00
May-20-25UpgradePiper SandlerNeutral → Overweight
Jan-10-25InitiatedBTIGBuy$6.00
May-12-23DowngradePiper SandlerOverweight → Neutral
Aug-03-22ReiteratedJefferiesBuy$8.00
Latest News
Jun-17-26
Jun-17-2607:50AM
Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue14011315
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A810
Gross Profit13211315
Selling, General and Administrative Excl. Other157147169
Research and Development232208190
Other Operating Expense6140
Operating Income-262-256-344
Interest Expense112113132
Unusual Expense
———
Non-Operating Income (Expense)481-17-62
Net Income Before Taxes-854-352-414
Income Taxes000
Consolidated Net Income-855-351-414
Net Income From Continuing Operations-855-351-414
Net Income-855-351-414
EPS (Recurring)-0.85-0.38-0.59
EPS (Basic, Before Extraordinaries)-0.85-0.38-0.59
EPS (Diluted)-0.85-0.38-0.62
EBITDA-727-224-264
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio53.9916.12—
Gross Margin94.29100.00100.00
Operating Margin-187.14-226.55-2,293.33
Net Margin-610.71-310.62-2,760.00
Shares Outstanding1,027920697
Market Capitalization7,5591,822—
Operating Lease Expense
———
Insider Trading Volume
$8.30$7.47$6.64$5.82$4.99● Close Price0.00M0.73M1.47M2.20M2.93MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Simon Barry J.DirectorJun 04 '26Sale7.1823,033165,3062,827,788Jun 05 12:00 AM
Simon Barry J.DirectorFeb 24 '26Sale12.0175,000900,7882,850,821Feb 26 12:00 AM
Selecky ChristobelDirectorFeb 23 '26Option Exercise2.9850,000149,00067,937Feb 24 12:00 AM
Selecky ChristobelDirectorFeb 23 '26Sale10.0025,000250,0000Feb 24 12:00 AM
Simon Barry J.DirectorFeb 23 '26Sale10.25165,0001,691,1022,925,821Feb 24 12:00 AM
LAUER REGAN JChief Accounting OfficerFeb 22 '26Option Exercise0.008,1300117,548Feb 24 12:00 AM
Sachs David C.Chief Financial OfficerFeb 22 '26Option Exercise0.0081,3000320,825Feb 24 12:00 AM
SOON-SHIONG PATRICKSee remarksFeb 22 '26Option Exercise0.00228,658029,816,081Feb 24 12:00 AM
Adcock RichardCEO & PresidentFeb 22 '26Option Exercise0.00304,8780637,904Feb 24 12:00 AM
Simon Barry J.DirectorFeb 22 '26Option Exercise0.0030,48603,096,847Feb 24 12:00 AM
Simon Barry J.DirectorFeb 20 '26Sale9.2510,00092,5003,081,604Feb 24 12:00 AM
SOON-SHIONG PATRICKSee remarksFeb 10 '26Option Exercise0.00548,244029,820,312Feb 12 12:00 AM
Sachs David C.Chief Financial OfficerFeb 10 '26Option Exercise0.00164,4720322,818Feb 12 12:00 AM
LAUER REGAN JChief Accounting OfficerFeb 10 '26Option Exercise0.0010,9640115,740Feb 12 12:00 AM
Adcock RichardCEO & PresidentFeb 10 '26Option Exercise0.00548,2440625,513Feb 12 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR